16:06 EST Mirum Pharmaceuticals (MIRM) sees FY25 product sales of $420M-$435M vs. $336.4M in FY24
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals announces FDA approval for Ctexli tablets
- MIRM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- FDA approves Mirum treatment for cerebrotendinous xanthomatosis
- Metagenomi appoints Eric Bjerkholt to board of directors
- Mirum Pharmaceuticals sees FY24 revenue $336M, consensus $332.78M